Related Experiment Video
Updated: Jul 31, 2026
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
[Tumor necrosis factor blocking agents: a review. Part I: Clinical efficacy evaluation].
C Rodríguez Moreno1, P López Vázquez, C Durán Parrondo
1Servicios de Farmacología Clínica, Complexo Hospitalario Universitario, Santiago de Compostela, a Coruña, Spain. carlos.rodríguez.moreno@sergas.es
Anales De Medicina Interna (Madrid, Spain : 1984)
|March 18, 2006
Summary
Monoclonal antibodies targeting tumor necrosis factor (TNF) effectively treat autoimmune diseases like rheumatoid arthritis but carry risks. This review examines TNF-blocker benefits and risks for informed clinical use.
Area of Science:
- Immunology
- Rheumatology
- Gastroenterology
Context:
- Tumor necrosis factor (TNF) blockade with monoclonal antibodies represents a significant advancement in managing autoimmune conditions.
- Approved indications include rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Crohn's disease.
- These therapies demonstrate efficacy in symptom reduction and disease progression modification.
Purpose:
- To review the evidence on the benefits and risks of TNF-blockers in their approved indications.
- To provide practical recommendations for the clinical management of patients using TNF-blockers.
Summary:
- TNF-blockers are effective in treating several autoimmune diseases by inhibiting inflammatory pathways.
- However, their use can disrupt immune homeostasis, leading to potential adverse events.
- Balancing therapeutic benefits against risks is crucial for optimal patient outcomes.
Impact:
- Provides clinicians with evidence-based guidance for the safe and effective use of TNF-blockers.
- Aims to optimize treatment strategies for autoimmune diseases, improving patient quality of life.
- Highlights the need for careful patient selection and monitoring during TNF-blocker therapy.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...